Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood.

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease, characterized by the progressive loss of motor neurons within the central nervous system. Neural degeneration and inflammatory processes, including activation of the complement system are hallmarks of this pathology. Our past work in ALS animal models (hSOD1 G93A rodents) has revealed… (More)

Topics

Cite this paper

@article{Mantovani2014ElevationOT, title={Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood.}, author={Susanna Mantovani and R. Gordon and J K Macmaw and C M M Pfluger and R. D. Henderson and Peter Noakes and P. A. McCombe and T. M. Woodruff}, journal={Journal of neuroimmunology}, year={2014}, volume={276 1-2}, pages={213-8} }